Please assess the completion status of the following clinical trial:

Trial Title: A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of B- or T-cell non-Hodgkin's lymphoma (NHL)~  * Intermediate histology B-cell NHL, including any of the following:~    * Diffuse large B-cell lymphoma~   * Transformed large cell lymphoma~ * Any T-cell NHL histology~ * Cutaneous T-cell lymphoma (CTCL) or mycosis fungoides (MF) allowed~* Relapsed or refractory disease, defined as disease progressed after prior complete remission (CR), partial remission (PR), or stable disease (SD) to last therapy OR failure to achieve CR, PR, or SD after completion of last therapy~* Must have received 1-3 prior therapeutic regimens~  * Cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (CHOP) AND cyclophosphamide, vincristine, and prednisone (CVP) OR CHOP with rituximab (CHOP-R) AND CVP with rituximab (CVP-R) is considered 1 regimen~ * Monoclonal antibody (e.g., rituximab) given as maintenance therapy is considered 1 regimen~ * Salvage chemotherapy followed by an autologous stem cell transplant is considered 1 regimen~ * No more than 7 prior therapeutic regimens for patients with CTCL or MF~* No mantle cell lymphoma~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy \> 3 months~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~  * At least 50,000/mm\^3 if documented bone marrow involvement~* Hemoglobin ≥ 8.0 g/dL~* AST and ALT ≤ 3 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 3 times ULN~* Bilirubin ≤ 2 times ULN~* Creatinine ≤ 2.0 mg/dL~* No known history of HIV infection~* No other active infection~* No uncontrolled hypertension~* No peripheral neuropathy ≥ grade 2 within the past 2 weeks~* No myocardial infarction within the past 6 months~* No New York Heart Association class III or IV heart failure~* No uncontrolled angina~* No severe uncontrolled ventricular arrhythmias~* No acute ischemia or active conduction system abnormalities by ECG~* No hypersensitivity to bortezomib, boron, or mannitol~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier-method contraception~* No serious medical or psychiatric illness that would preclude study participation~PRIOR CONCURRENT THERAPY:~* Prior autologous and/or allogeneic stem cell transplantation allowed~* More than 3 weeks since prior chemotherapy, radiotherapy, or immunotherapy~* More than 3 weeks since prior systemic biologic anticancer therapy~* More than 3 weeks since prior systemic corticosteroids (e.g., oral prednisone \> 10 mg per day)~* More than 2 weeks since prior investigational drug~* No prior bortezomib or gemcitabine hydrochloride~* No other concurrent systemic cytotoxic chemotherapy or investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine 800 mg/m2 + Bortezomib IVP over 3-5 seconds (Type: EXPERIMENTAL): Gemcitabine dose of 800 mg/m2 over 30 minutes followed by Bortezomib IVP given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy